Active Pharmaceutical Ingredient (API) Market in US 2025-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	177 Pages	TechNavio	May, 2025	INF20056808

Best Price Guarantee
Price	from $2,500
Length	177 Pages
Publisher	TechNavio
Published Date	May, 2025
SKU	INF20056808

Active Pharmaceutical Ingredient (API) Market In US 2025-2029

The active pharmaceutical ingredient (API) market in us is forecasted to grow by USD 25456.1 mn during 2024-2029, accelerating at a CAGR of 9% during the forecast period. The report on the active pharmaceutical ingredient (API) market in us provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of type ii drug master files (DMF), growing prevalence of chronic conditions, and increasing demand for biopharmaceuticals and biosimilars.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's active pharmaceutical ingredient (API) market in us is segmented as below:

By Type

Captive API
Contract API

By Product

Generic
Innovative

By Application

Oncology
Cardiovascular diseases
Diabetes
Communicable diseases
Others

This study identifies the paradigm shift in api manufacturing as one of the prime reasons driving the active pharmaceutical ingredient (API) market in us growth during the next few years. Also, increasing patent exercises and growing focus on production of high-value apis will lead to sizable demand in the market.

The report on the active pharmaceutical ingredient (API) market in us covers the following areas:

Active Pharmaceutical Ingredient (API) Market in US sizing
Active Pharmaceutical Ingredient (API) Market in US forecast
Active Pharmaceutical Ingredient (API) Market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (API) market in us vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Inc., Dr Reddys Laboratories Ltd., DSM-Firmenich AG, GlaxoSmithKline Plc, Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Also, the active pharmaceutical ingredient (API) market in us analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Country Market Characteristics; Executive Summary - Chart on Market Segmentation by Type; Executive Summary - Chart on Market Segmentation by Product; Executive Summary - Chart on Market Segmentation by Application; Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis: 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 2.2 Criticality of inputs and Factors of differentiation; Overview on criticality of inputs and factors of differentiation; 2.3 Factors of disruption; Overview on factors of disruption; 2.4 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029
3 Market Landscape: 3.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 3.2 Market characteristics; Market characteristics analysis; 3.3 Value chain analysis; Value chain analysis
4 Market Sizing: 4.1 Market definition; Offerings of companies included in the market definition; 4.2 Market segment analysis; Market segments; 4.3 Market size 2024; 4.4 Market outlook: Forecast for 2024-2029; Chart on US - Market size and forecast 2024-2029 ($ million); Data Table on US - Market size and forecast 2024-2029 ($ million); Chart on US: Year-over-year growth 2024-2029 (%); Data Table on US: Year-over-year growth 2024-2029 (%)
5 Historic Market Size: 5.1 Active Pharmaceutical Ingredient (API) Market in US 2019 - 2023; Historic Market Size - Data Table on Active Pharmaceutical Ingredient (API) Market in US 2019 - 2023 ($ million); 5.2 Type segment analysis 2019 - 2023; Historic Market Size - Type Segment 2019 - 2023 ($ million); 5.3 Product segment analysis 2019 - 2023; Historic Market Size - Product Segment 2019 - 2023 ($ million); 5.4 Application segment analysis 2019 - 2023; Historic Market Size - Application Segment 2019 - 2023 ($ million)
6 Qualitative Analysis: 6.1 The AI impact on active pharmaceutical ingredient (API) market in US
7 Five Forces Analysis: 7.1 Five forces summary; Five forces analysis - Comparison between 2024 and 2029; 7.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2024 and 2029; 7.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2024 and 2029; 7.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2024 and 2029; 7.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2024 and 2029; 7.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2024 and 2029; 7.7 Market condition; Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type: 8.1 Market segments; Chart on Type - Market share 2024-2029 (%); Data Table on Type - Market share 2024-2029 (%); 8.2 Comparison by Type; Chart on Comparison by Type; Data Table on Comparison by Type; 8.3 Captive API - Market size and forecast 2024-2029; Chart on Captive API - Market size and forecast 2024-2029 ($ million); Data Table on Captive API - Market size and forecast 2024-2029 ($ million); Chart on Captive API - Year-over-year growth 2024-2029 (%); Data Table on Captive API - Year-over-year growth 2024-2029 (%); 8.4 Contract API - Market size and forecast 2024-2029; Chart on Contract API - Market size and forecast 2024-2029 ($ million); Data Table on Contract API - Market size and forecast 2024-2029 ($ million); Chart on Contract API - Year-over-year growth 2024-2029 (%); Data Table on Contract API - Year-over-year growth 2024-2029 (%); 8.5 Market opportunity by Type; Market opportunity by Type ($ million); Data Table on Market opportunity by Type ($ million)
9 Market Segmentation by Product: 9.1 Market segments; Chart on Product - Market share 2024-2029 (%); Data Table on Product - Market share 2024-2029 (%); 9.2 Comparison by Product; Chart on Comparison by Product; Data Table on Comparison by Product; 9.3 Generic - Market size and forecast 2024-2029; Chart on Generic - Market size and forecast 2024-2029 ($ million); Data Table on Generic - Market size and forecast 2024-2029 ($ million); Chart on Generic - Year-over-year growth 2024-2029 (%); Data Table on Generic - Year-over-year growth 2024-2029 (%); 9.4 Innovative - Market size and forecast 2024-2029; Chart on Innovative - Market size and forecast 2024-2029 ($ million); Data Table on Innovative - Market size and forecast 2024-2029 ($ million); Chart on Innovative - Year-over-year growth 2024-2029 (%); Data Table on Innovative - Year-over-year growth 2024-2029 (%); 9.5 Market opportunity by Product; Market opportunity by Product ($ million); Data Table on Market opportunity by Product ($ million)
10 Market Segmentation by Application: 10.1 Market segments; Chart on Application - Market share 2024-2029 (%); Data Table on Application - Market share 2024-2029 (%); 10.2 Comparison by Application; Chart on Comparison by Application; Data Table on Comparison by Application; 10.3 Oncology - Market size and forecast 2024-2029; Chart on Oncology - Market size and forecast 2024-2029 ($ million); Data Table on Oncology - Market size and forecast 2024-2029 ($ million); Chart on Oncology - Year-over-year growth 2024-2029 (%); Data Table on Oncology - Year-over-year growth 2024-2029 (%); 10.4 Cardiovascular diseases - Market size and forecast 2024-2029; Chart on Cardiovascular diseases - Market size and forecast 2024-2029 ($ million); Data Table on Cardiovascular diseases - Market size and forecast 2024-2029 ($ million); Chart on Cardiovascular diseases - Year-over-year growth 2024-2029 (%); Data Table on Cardiovascular diseases - Year-over-year growth 2024-2029 (%); 10.5 Diabetes - Market size and forecast 2024-2029; Chart on Diabetes - Market size and forecast 2024-2029 ($ million); Data Table on Diabetes - Market size and forecast 2024-2029 ($ million); Chart on Diabetes - Year-over-year growth 2024-2029 (%); Data Table on Diabetes - Year-over-year growth 2024-2029 (%); 10.6 Communicable diseases - Market size and forecast 2024-2029; Chart on Communicable diseases - Market size and forecast 2024-2029 ($ million); Data Table on Communicable diseases - Market size and forecast 2024-2029 ($ million); Chart on Communicable diseases - Year-over-year growth 2024-2029 (%); Data Table on Communicable diseases - Year-over-year growth 2024-2029 (%); 10.7 Others - Market size and forecast 2024-2029; Chart on Others - Market size and forecast 2024-2029 ($ million); Data Table on Others - Market size and forecast 2024-2029 ($ million); Chart on Others - Year-over-year growth 2024-2029 (%); Data Table on Others - Year-over-year growth 2024-2029 (%); 10.8 Market opportunity by Application; Market opportunity by Application ($ million); Data Table on Market opportunity by Application ($ million)
11 Customer Landscape: 11.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Drivers, Challenges, and Opportunity/Restraints: 12.1 Market drivers; 12.2 Market challenges; 12.3 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029; 12.4 Market opportunities/restraints
13 Competitive Landscape: 13.1 Overview; 13.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 13.3 Landscape disruption; Overview on factors of disruption; 13.4 Industry risks; Impact of key risks on business
14 Competitive Analysis: 14.1 Companies profiled; Companies covered; 14.2 Company ranking index; Company ranking index; 14.3 Market positioning of companies; Matrix on companies position and classification; 14.4 AbbVie Inc.; AbbVie Inc. - Overview; AbbVie Inc. - Product / Service; AbbVie Inc. - Key news; AbbVie Inc. - Key offerings; SWOT; 14.5 Amneal Pharmaceuticals Inc.; Amneal Pharmaceuticals Inc. - Overview; Amneal Pharmaceuticals Inc. - Business segments; Amneal Pharmaceuticals Inc. - Key news; Amneal Pharmaceuticals Inc. - Key offerings; Amneal Pharmaceuticals Inc. - Segment focus; SWOT; 14.6 Aurobindo Pharma Ltd.; Aurobindo Pharma Ltd. - Overview; Aurobindo Pharma Ltd. - Product / Service; Aurobindo Pharma Ltd. - Key offerings; SWOT; 14.7 Cadila Pharmaceuticals Ltd.; Cadila Pharmaceuticals Ltd. - Overview; Cadila Pharmaceuticals Ltd. - Product / Service; Cadila Pharmaceuticals Ltd. - Key offerings; SWOT; 14.8 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; SWOT; 14.9 Dr Reddys Laboratories Ltd.; Dr Reddys Laboratories Ltd. - Overview; Dr Reddys Laboratories Ltd. - Business segments; Dr Reddys Laboratories Ltd. - Key news; Dr Reddys Laboratories Ltd. - Key offerings; Dr Reddys Laboratories Ltd. - Segment focus; SWOT; 14.10 DSM-Firmenich AG; DSM-Firmenich AG - Overview; DSM-Firmenich AG - Business segments; DSM-Firmenich AG - Key news; DSM-Firmenich AG - Key offerings; DSM-Firmenich AG - Segment focus; SWOT; 14.11 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; SWOT; 14.12 Lupin Ltd.; Lupin Ltd. - Overview; Lupin Ltd. - Business segments; Lupin Ltd. - Key news; Lupin Ltd. - Key offerings; Lupin Ltd. - Segment focus; SWOT; 14.13 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; SWOT; 14.14 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; SWOT; 14.15 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; SWOT; 14.16 Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd. - Overview; Sun Pharmaceutical Industries Ltd. - Product / Service; Sun Pharmaceutical Industries Ltd. - Key news; Sun Pharmaceutical Industries Ltd. - Key offerings; SWOT; 14.17 Teva Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd. - Overview; Teva Pharmaceutical Industries Ltd. - Business segments; Teva Pharmaceutical Industries Ltd. - Key news; Teva Pharmaceutical Industries Ltd. - Key offerings; Teva Pharmaceutical Industries Ltd. - Segment focus; SWOT; 14.18 Viatris Inc.; Viatris Inc. - Overview; Viatris Inc. - Business segments; Viatris Inc. - Key news; Viatris Inc. - Key offerings; Viatris Inc. - Segment focus; SWOT
15 Appendix: 15.1 Scope of the report; 15.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 15.3 Currency conversion rates for US$; Currency conversion rates for US$; 15.4 Research methodology; Research methodology; 15.5 Data procurement; Information sources; 15.6 Data validation; Data validation; 15.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 15.8 Data synthesis; Data synthesis; 15.9 360 degree market analysis; 360 degree market analysis; 15.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Type; Exhibits5: Executive Summary - Chart on Market Segmentation by Product; Exhibits6: Executive Summary - Chart on Market Segmentation by Application; Exhibits7: Executive Summary - Chart on Company Market Positioning; Exhibits8: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits9: Overview on criticality of inputs and factors of differentiation; Exhibits10: Overview on factors of disruption; Exhibits11: Impact of drivers and challenges in 2024 and 2029; Exhibits12: Parent Market; Exhibits13: Data Table on - Parent Market; Exhibits14: Market characteristics analysis; Exhibits15: Value chain analysis; Exhibits16: Offerings of companies included in the market definition; Exhibits17: Market segments; Exhibits18: Chart on US - Market size and forecast 2024-2029 ($ million); Exhibits19: Data Table on US - Market size and forecast 2024-2029 ($ million); Exhibits20: Chart on US: Year-over-year growth 2024-2029 (%); Exhibits21: Data Table on US: Year-over-year growth 2024-2029 (%); Exhibits22: Historic Market Size - Data Table on Active Pharmaceutical Ingredient (API) Market in US 2019 - 2023 ($ million); Exhibits23: Historic Market Size - Type Segment 2019 - 2023 ($ million); Exhibits24: Historic Market Size - Product Segment 2019 - 2023 ($ million); Exhibits25: Historic Market Size - Application Segment 2019 - 2023 ($ million); Exhibits26: Five forces analysis - Comparison between 2024 and 2029; Exhibits27: Bargaining power of buyers - Impact of key factors 2024 and 2029; Exhibits28: Bargaining power of suppliers - Impact of key factors in 2024 and 2029; Exhibits29: Threat of new entrants - Impact of key factors in 2024 and 2029; Exhibits30: Threat of substitutes - Impact of key factors in 2024 and 2029; Exhibits31: Threat of rivalry - Impact of key factors in 2024 and 2029; Exhibits32: Chart on Market condition - Five forces 2024 and 2029; Exhibits33: Chart on Type - Market share 2024-2029 (%); Exhibits34: Data Table on Type - Market share 2024-2029 (%); Exhibits35: Chart on Comparison by Type; Exhibits36: Data Table on Comparison by Type; Exhibits37: Chart on Captive API - Market size and forecast 2024-2029 ($ million); Exhibits38: Data Table on Captive API - Market size and forecast 2024-2029 ($ million); Exhibits39: Chart on Captive API - Year-over-year growth 2024-2029 (%); Exhibits40: Data Table on Captive API - Year-over-year growth 2024-2029 (%); Exhibits41: Chart on Contract API - Market size and forecast 2024-2029 ($ million); Exhibits42: Data Table on Contract API - Market size and forecast 2024-2029 ($ million); Exhibits43: Chart on Contract API - Year-over-year growth 2024-2029 (%); Exhibits44: Data Table on Contract API - Year-over-year growth 2024-2029 (%); Exhibits45: Market opportunity by Type ($ million); Exhibits46: Data Table on Market opportunity by Type ($ million); Exhibits47: Chart on Product - Market share 2024-2029 (%); Exhibits48: Data Table on Product - Market share 2024-2029 (%); Exhibits49: Chart on Comparison by Product; Exhibits50: Data Table on Comparison by Product; Exhibits51: Chart on Generic - Market size and forecast 2024-2029 ($ million); Exhibits52: Data Table on Generic - Market size and forecast 2024-2029 ($ million); Exhibits53: Chart on Generic - Year-over-year growth 2024-2029 (%); Exhibits54: Data Table on Generic - Year-over-year growth 2024-2029 (%); Exhibits55: Chart on Innovative - Market size and forecast 2024-2029 ($ million); Exhibits56: Data Table on Innovative - Market size and forecast 2024-2029 ($ million); Exhibits57: Chart on Innovative - Year-over-year growth 2024-2029 (%); Exhibits58: Data Table on Innovative - Year-over-year growth 2024-2029 (%); Exhibits59: Market opportunity by Product ($ million); Exhibits60: Data Table on Market opportunity by Product ($ million); Exhibits61: Chart on Application - Market share 2024-2029 (%); Exhibits62: Data Table on Application - Market share 2024-2029 (%); Exhibits63: Chart on Comparison by Application; Exhibits64: Data Table on Comparison by Application; Exhibits65: Chart on Oncology - Market size and forecast 2024-2029 ($ million); Exhibits66: Data Table on Oncology - Market size and forecast 2024-2029 ($ million); Exhibits67: Chart on Oncology - Year-over-year growth 2024-2029 (%); Exhibits68: Data Table on Oncology - Year-over-year growth 2024-2029 (%); Exhibits69: Chart on Cardiovascular diseases - Market size and forecast 2024-2029 ($ million); Exhibits70: Data Table on Cardiovascular diseases - Market size and forecast 2024-2029 ($ million); Exhibits71: Chart on Cardiovascular diseases - Year-over-year growth 2024-2029 (%); Exhibits72: Data Table on Cardiovascular diseases - Year-over-year growth 2024-2029 (%); Exhibits73: Chart on Diabetes - Market size and forecast 2024-2029 ($ million); Exhibits74: Data Table on Diabetes - Market size and forecast 2024-2029 ($ million); Exhibits75: Chart on Diabetes - Year-over-year growth 2024-2029 (%); Exhibits76: Data Table on Diabetes - Year-over-year growth 2024-2029 (%); Exhibits77: Chart on Communicable diseases - Market size and forecast 2024-2029 ($ million); Exhibits78: Data Table on Communicable diseases - Market size and forecast 2024-2029 ($ million); Exhibits79: Chart on Communicable diseases - Year-over-year growth 2024-2029 (%); Exhibits80: Data Table on Communicable diseases - Year-over-year growth 2024-2029 (%); Exhibits81: Chart on Others - Market size and forecast 2024-2029 ($ million); Exhibits82: Data Table on Others - Market size and forecast 2024-2029 ($ million); Exhibits83: Chart on Others - Year-over-year growth 2024-2029 (%); Exhibits84: Data Table on Others - Year-over-year growth 2024-2029 (%); Exhibits85: Market opportunity by Application ($ million); Exhibits86: Data Table on Market opportunity by Application ($ million); Exhibits87: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits88: Impact of drivers and challenges in 2024 and 2029; Exhibits89: Overview on criticality of inputs and factors of differentiation; Exhibits90: Overview on factors of disruption; Exhibits91: Impact of key risks on business; Exhibits92: Companies covered; Exhibits93: Company ranking index; Exhibits94: Matrix on companies position and classification; Exhibits95: AbbVie Inc. - Overview; Exhibits96: AbbVie Inc. - Product / Service; Exhibits97: AbbVie Inc. - Key news; Exhibits98: AbbVie Inc. - Key offerings; Exhibits99: SWOT; Exhibits100: Amneal Pharmaceuticals Inc. - Overview; Exhibits101: Amneal Pharmaceuticals Inc. - Business segments; Exhibits102: Amneal Pharmaceuticals Inc. - Key news; Exhibits103: Amneal Pharmaceuticals Inc. - Key offerings; Exhibits104: Amneal Pharmaceuticals Inc. - Segment focus; Exhibits105: SWOT; Exhibits106: Aurobindo Pharma Ltd. - Overview; Exhibits107: Aurobindo Pharma Ltd. - Product / Service; Exhibits108: Aurobindo Pharma Ltd. - Key offerings; Exhibits109: SWOT; Exhibits110: Cadila Pharmaceuticals Ltd. - Overview; Exhibits111: Cadila Pharmaceuticals Ltd. - Product / Service; Exhibits112: Cadila Pharmaceuticals Ltd. - Key offerings; Exhibits113: SWOT; Exhibits114: Cipla Inc. - Overview; Exhibits115: Cipla Inc. - Business segments; Exhibits116: Cipla Inc. - Key news; Exhibits117: Cipla Inc. - Key offerings; Exhibits118: Cipla Inc. - Segment focus; Exhibits119: SWOT; Exhibits120: Dr Reddys Laboratories Ltd. - Overview; Exhibits121: Dr Reddys Laboratories Ltd. - Business segments; Exhibits122: Dr Reddys Laboratories Ltd. - Key news; Exhibits123: Dr Reddys Laboratories Ltd. - Key offerings; Exhibits124: Dr Reddys Laboratories Ltd. - Segment focus; Exhibits125: SWOT; Exhibits126: DSM-Firmenich AG - Overview; Exhibits127: DSM-Firmenich AG - Business segments; Exhibits128: DSM-Firmenich AG - Key news; Exhibits129: DSM-Firmenich AG - Key offerings; Exhibits130: DSM-Firmenich AG - Segment focus; Exhibits131: SWOT; Exhibits132: GlaxoSmithKline Plc - Overview; Exhibits133: GlaxoSmithKline Plc - Business segments; Exhibits134: GlaxoSmithKline Plc - Key news; Exhibits135: GlaxoSmithKline Plc - Key offerings; Exhibits136: GlaxoSmithKline Plc - Segment focus; Exhibits137: SWOT; Exhibits138: Lupin Ltd. - Overview; Exhibits139: Lupin Ltd. - Business segments; Exhibits140: Lupin Ltd. - Key news; Exhibits141: Lupin Ltd. - Key offerings; Exhibits142: Lupin Ltd. - Segment focus; Exhibits143: SWOT; Exhibits144: Novartis AG - Overview; Exhibits145: Novartis AG - Business segments; Exhibits146: Novartis AG - Key news; Exhibits147: Novartis AG - Key offerings; Exhibits148: Novartis AG - Segment focus; Exhibits149: SWOT